Roche Australia have advised that availability of tocilizumab (Actemra) in Australia is improving but supply disruptions to some tocilizumab products will continue beyond January 2022.
The 2021 Advertising Code takes effect on 1 January 2022 and will be subject to a 6-month transition period until 30 June 2022 where both the 2018 and 2021 Advertising Codes will apply.